Physician profile
Deepak Raja
NPI 1215143771
$61,703.27
in general payments reported to CMS, 2019-2025
33 companies · $8,093 in 2025
The $8,093 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $3,081 · 2021: $6,256 · 2022: $8,971 · 2023: $5,308 · 2024: $14K · 2025: $8,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $6,494 · Consulting Fee: $4,888 · Travel and Lodging: $2,750 · Education: $27.86 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,575.00 |
| Food and Beverage | $6,494.10 |
| Consulting Fee | $4,887.50 |
| Travel and Lodging | $2,749.64 |
| Education | $27.86 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18,708.39 | 2024-2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $13,596.39 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $9,376.66 | 2019-2023 | |
| Shire North American Group INC | $3,955.46 | 2019 | |
| Dompe US, INC. | $3,324.18 | 2019-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $1,808.67 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $1,641.83 | 2023-2025 | Cirrus Hd-Oct, Artevo 800, Visumax |
| Biotissue Holdings INC. | $1,641.79 | 2020-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $1,596.72 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Alcon Vision LLC | $855.78 | 2019-2025 | Tryptyr, Clareon Panoptix Pro, Rocklatan |
| Bausch & Lomb Americas INC. | $731.22 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Oyster Point Pharma, INC. | $603.48 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $596.89 | 2024-2025 | Vevye |
| Abbvie INC. | $591.89 | 2022-2025 | |
| Allergan, INC. | $538.78 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $476.23 | 2019-2021 | |
| Horizon Therapeutics Plc | $386.47 | 2021-2023 | Tepezza |
| Sight Sciences, INC. | $315.47 | 2019-2024 | Tearcare System |
| Tarsus Pharmaceuticals, INC. | $288.38 | 2024-2025 | Xdemvy |
| Merz Pharmaceuticals, LLC | $97.57 | 2024-2025 | Xeomin |
| Rayner Intraocular Lenses Limited | $89.72 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Rxsight INC | $83.90 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $82.21 | 2019-2021 | |
| Glaukos Corporation | $73.00 | 2019-2024 | Idose |
| Eyevance Pharmaceuticals LLC | $54.74 | 2019-2021 | |
| Iridex Corporation | $40.63 | 2019-2021 | |
| Thea Pharma INC. | $31.82 | 2024 | Iyuzeh |
| Mallinckrodt Enterprises LLC | $22.12 | 2019 | |
| Ocular Therapeutix, INC. | $21.05 | 2023 | Dextenza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Apellis Pharmaceuticals, INC. | $18.27 | 2025 | Syfovre |
| Tearlab Corp | $17.86 | 2024 | Scoutpro Osmolarity System |
| Dutch Ophthalmic, USA | $16.30 | 2025 | Tissueblue, Eva, Combined Machine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Raja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.